Escitalopram, duloxetine and agomelatine outperform fluoxetine in preventing depression symptoms from returning over time, according to a major new study published in The Lancet Psychiatry.
- Researchers analyzed 115 previous clinical trials involving more than 30,000 people at Radboud University Medical Center in the Netherlands.
- Escitalopram, duloxetine and agomelatine showed better long-term results than fluoxetine, which served as the primary comparison drug.
- Experts caution that treatment must balance benefits and side effects individually, as agomelatine carries a risk of liver failure and is not approved in the U.S.
Researchers evaluated 20 antidepressants to determine how well they eased depression symptoms and maintained wellness over time. They combined results from 115 previous clinical trials covering more than 30,000 people, a news release from Radboud University Medical Center stated.
The analysis identified three medications that performed better over the long term than fluoxetine. Those drugs include escitalopram, sold under the brand name Lexapro; duloxetine, sold as Cymbalta; and agomelatine.
Eli Lilly said that it discontinued manufacturing Prozac in 2024. The company said that fluoxetine remains accessible through various U.S. Food and Drug Administration-approved generic medications, emphasizing that neither the research paper nor the university press release explicitly mentioned Prozac or any item made by Lilly.
“Escitalopram is already widely used,” Paul van Haaren, a researcher at Radboud University Medical Center who worked on the study, said in the release. “Agomelatine works well, but one of its side effects is the risk of liver failure. Duloxetine is less well-known and is prescribed less frequently as a first-line treatment.”
Escitalopram belongs to a group of medications known as selective serotonin reuptake inhibitors, or SSRIs. These medications are often recommended as a first option for treating depression.
Out of all the SSRIs evaluated in the research, escitalopram demonstrated superior effectiveness in supporting patients’ long-term wellness. According to Eric Ruhé, a professor specializing in treatment-resistant depression at Radboud University Medical Center, these results might eventually change how physicians select antidepressant treatments.
“As a prescriber, you consider the balance between a medication’s benefits and side effects,” Ruhé told the release. “That balance differs from person to person.”
Dr. Carole Lieberman, a Beverly Hills, California-based psychiatrist with board certification who did not participate in the research, advised caution when evaluating the results. She said that agomelatine is not approved in the U.S.
“The best way to treat someone with depression is not always with antidepressants, and certainly not with antidepressants alone,” Lieberman told Fox News Digital.
Lieberman said that talk therapy or psychotherapy can also serve a crucial function in depression treatment, and said that certain individuals may experience advantages from combining pharmaceutical drugs with counseling.
| Medication | Common Brand Name | Drug Class |
|---|---|---|
| Escitalopram | Lexapro | SSRI |
| Duloxetine | Cymbalta | SNRI |
| Fluoxetine | Prozac (Discontinued 2024) | SSRI |
The researchers acknowledged limitations in their methodology. Rather than enrolling a new group of patients and following them over time, the team combined results from previous clinical trials.
The findings cannot predict which antidepressant will work best for a specific individual. Researchers stressed that doctors and patients should consider potential benefits and side effects when choosing a medication.
The publication advised that individuals having inquiries regarding their antidepressant prescriptions ought to consult their physician prior to altering any medication regimens.